DNMT1 and neoplasm: Tumor-bearing mice with LKB1 loss and human LKB1-mutant pancreatic tumor cells are more sensitized to DNMT knockdown or DNMT inhibitor decitabine treatment, which inhibits serine biosynthesis and DNA methylation (Kottakis et al., 2016).